Down syndrome (DS) is the most common form of viable chromosomal abnormality. DS is associated with recurrent infections, auto-immunity and malignancies in children. Little is known about immunity and infections in DS at adulthood.
Methods
We studied two separate group of adults (> 18 years old) with DS in a single referral tertiary center (Strasbourg University Hospital). The first group included 37 ambulatory DS patients between November 2014 and May 2017. We analyzed exhaustive serological and immunobiological parameters, at one point, together with the prevalence of infections, autoimmune manifestations and malignancies. The second group included 64 hospitalized patients (138 stays) in the same center, between January 2005 and December 2016.
Results
One hundred and one adult patients with DS were included. Unlike children and despite a global lymphopenia, adults with DS underwent few infections in our ambulatory group. They did not experience any malignancy and, apart from hypothyroidism, they presented only occasional autoimmune manifestations. Hospitalized DS patients were older than ambulatory ones (median age 47 years (18–73) vs. 27 (18–52), p < 0.0001) and admitted mostly for infections (76.8%). Infections were associated with epilepsy and dementia (OR 6.5 (2.2–19), p = 0.001; p = 0.0006 in multivariate analysis) and higher mortality (OR 7.4 (1.4–37), p = 0.01).
Conclusion
Despite persistent immunobiological abnormalities at adulthood, young ambulatory adults with DS remain healthy with a low rate of infections. Infections are associated with neurological degeneration and increase the mortality arguing for a dedicated support of older DS patients.
Trial registration
ClinicalTrials.gov: NCT01663675 (August 13, 2012). Hospital Clinical Research Program (PHRC): number 2012-A00466–37 (Dr Y. Alembik).
International Classification of Diseases (version 10)
mAb
monoclonal Antibody
PID
Primary Immune Deficiency
Introduction
Down syndrome (DS) caused by trisomy 21 is the most common form of viable chromosome abnormality in children and the prevalence of DS continues to increase with life expectancy [1]. Survival of patients with DS improved drastically in the past few decades, with the detection and the early surgical care of congenital heart malformations (atrioventricular septal, ventricular septal, and atrial septal defects or persistent patent ductus arteriosus) [2]. The median age at death is now mid-50’s compared to 10 years of age in the 1970’s [3, 4]. Children with DS have a high incidence of infections of the respiratory tracts [5]. Over the last 3 decades, these infections have been linked to both innate and adaptive immunological abnormalities. Studies describing the immune system of infants with DS report the reduction and an altered distribution of T and B cell populations [6, 7] coupled to a poor response to vaccines [8‐11]. Thus, it has been suggested that children with DS share similarities with patients affected with primary immunodeficiency (PID) and some PIDs classifications include DS [12, 13]. In contrast with pediatric literature, there is a lack of information about infections and immune parameters in adults with DS. Herein we report the features of 101 adults with DS.
Methods
Following approvement of our Institutional Boards, we studied two separate groups of adults (> 18 years old) with DS in Strasbourg University Hospital (Fig. 1). The first group included ambulatory DS patients (Department of Medical Genetic) between 2014 and 2017. We analyzed at one point serological and immunobiological parameters, together with the retrospective prevalence of infections, autoimmune manifestations and malignancies. The second group included hospitalized patients between 2005 and 2016 with associated DS ICD codes or key words “Down syndrome” or “Trisomy 21” in medical letters with the mean of systematic research by the medical information department of the hospital. We excluded patients hospitalized for scheduled exams.
×
Anzeige
We used Fisher’s exact test to compare qualitative variables and Student test for quantitative variables in univariate analysis. Mann-Whitney test was used to compare non-normally distributed variables. Multivariate analyzes were done for a p-value < 0.10 in univariate analysis using ridge logistic regression. Statistical significance was defined by p < 0.05 in 2-tailed tests.
Results
Thirty-seven patients came to the medical genetic consultation for DS (Table 1). Median age was 27 years (18–52). None was in institutional care. Frequent infections were reported during childhood for 20 DS patients (54%), the leading manifestations involving respiratory tract (49%) and ENT (16%). Only one patient was identified with recurrent infectious events after the age of 18. Total lymphocyte counts of DS patients were low when compared to standards (1480 cells/μL vs. 2170 cells/μL, p = 0.004) concerning especially naïve and memory B cell subsets as described in DS children. 15 patients presented with hypergammaglobulinemia (IgG > 15 g/L) and increased IgG1 and IgG3 levels. Serological status following vaccination for DPT (Diphteria, Polio and Tetanus), Streptococcus pneumoniae and Haemophilus influenzae showed protective titers in most cases.
Table 1
Ambulatory DS patients
Demographics and clinical characteristics of ambulatory DS patients
n = 37
Age at inclusion (years)
27 (18–52)
Sex ratio (F/M)
1.2 (20/17)
Institutional living (n, %)
0
Recurrent infections within childhood
Before 5 years old
18 (49%)
From 6 to 18 years old
17 (46%)
Recurrent respiratory tract infections at adulthooda
1 (2.7%)
Hypothyroidism
20 (54%)
Epilepsy
2 (5.1%)
Dementia
0
Cardiac congenital disease
13 (35%)
Urogenital malformation
0
Gastrointestinal malformation
2 (5.1%)
Type 1 diabetes
0
Celiac disease
1 (2.7%)
Hematological malignancy
0
Biological features of ambulatory DS patients
Normal values
Neutrophils (cells/μL)
1800-7900
2225 (1110-4970)
Lymphocytes (cells/μL)
1943-2709
1480 (801–3132)
T cells (cells/μL)
700–1900
1208 (514–2516)
CD4+ T cells (cells/μL)
400–1300
612 (273–1307)
CD8+ T cells (cells/μL)
200–700
474 (117–1365)
Naïve CD45RA+ (% of T-cells)
34–60%
31% (9–65)
Memory CD45RO+ (% of T-cells)
33–65%
65% (32–86)
Regulatory T cells CD3 + CD25 + FoxP3+ (% of CD4+)
a> 2 pneumoniae or bronchitis with need of antibiotherapy (after 18 years old) bAnti-TPO antibodies were searched for 26 patients c37patients were inoculated against diphteria tetanus and poliomyelitis (DTP vaccine), 35 (97%) against BCG (Bacillus of Calmette and Guerin), 27 (73%) against Bordetella pertussis, 8 (22%) against Haemophilus influenza type b and 2 (5%) against Streptococcus pneumoniae. Protective titers were defined using manufacturers’ values
During an 11 year period (2005–2016), 64 DS patients were hospitalized at Strasbourg University Hospital, mainly in Internal Medicine, Infectious diseases, Pneumology and Intensive Care Units corresponding to 138 stays (a total of 190,740 stays were recorded in the same departments during this period), (Table 2). Median age was 47 years (18–73), older than ambulatory ones (p < 0.0001). Thirty-seven patients (58%) were in institutional care. The outstanding causes for hospitalization among DS patients were infections (n = 106/138), mostly aspiration pneumonia (n = 91/138). When available, lymphocyte counts and Ig levels were comparable to those of the ambulatory patients. Infections were associated with epilepsy and dementia (OR 6.5 (2.2–19), p = 0.001; p = 0.0006 in multivariate analysis) and higher mortality (OR 7.4 (1.4–37), p = 0.01). We found a median of second infectious event at 6.9 months in the group with neurological diseases vs. more than 120 months in the group without neurological diseases (p = 0.002, Fig. 2). Furthermore, the annual rate of infection dramatically increased with age in hospitalized group with a 5 fold increase of incidental infections after 50 years (Additional file 1: Figure S1).
Table 2
Hospitalized DS patients (n = 64): comparison between DS patients with or without recurrent infections
Infectionsa
(n = 31)
No Infections
(n = 33)
OR
/HR
Univariate
p*
Multivariate
p**
Age (years)
51 (19–73)
45 (18–65)
/
0.01
0.12
Sex ratio (F/M)
0.35 (8/23)
0.8 (15/18)
0.41 (0.14–1.2)
0.12
0.16
Institutional living (n, %)
21 (68)
16 (48)
2.2 (0.8–6.1)
0.12
0.89
Hypothyroidism (n, %)
14 (45)
13 (40)
1.2 (0.46–3.4)
0.8
/
Cardiac congenital disease (n, %)
5 (16)
5 (15)
1.1 (0.27–4.1)
1
0.06
Gastrointestinal malformation (n, %)
2 (6.4)
2 (6)
1.1 (0.14–8.0)
1
/
Neurological diseaseb(n, %)
22 (71)
9 (27)
6.5 (2.2–19)
0.001
0.0006
Epilepsy (n, %)
16 (52)
7 (21)
3.9 (1.3–12)
0.02
/
Dementia (n, %)
13 (42)
3 (9)
7.2 (1.8–29)
0.003
/
Hematological malignancy (n, %)
0
1 (3)
0.34 (0.1–9)
1
/
Lymphocytes rate (/μL)
1340 (650–2580)
1575 (558–3710)
/
0.09
0.13
Lymphocytes < 1000/mm3 (n, %)
9 (29)
5 (15)
2.3 (0.67–7.8)
0.23
/
Immunoglobulin rate (g/L)
12 (7–23)
16 (9–18)
/
0.22
/
Mortality (n, %)
10 (32)
2 (6)
7.4 (1.4–37)
0.01
/
aTotal number of infectious events: 106 (/138 stays); intensive care unit admission 11/106; Need of pressor amines 7/106, Acute lung injury syndrome 3/18; Pneumonia 96/106 (91%). The other reasons were seizures (n = 8), heart failure (n = 5), occlusive syndrome (n = 5), arterial cardiovascular event (n = 5), syncope (n = 4), acute renal disease (n = 2), pancreatitis, venous thrombosis, deep weight loss (n = 1 each)
b Neurological disease was defined as epilepsy or dementia
*Difference between infections and no infections groups using Fischer’s test for categorical variables and Mann-Whitney test for quantitative variables
**Using multiple logistic regression. OR: Odd Ratio – HR: Hazard Ratio
Statistically significant results are marked in boldface
×
Discussion
In DS children, epidemiological [1, 14‐18] and pathophysiological [6, 19‐22] evidences argue for a higher risk of infectious events, hematological malignancies and autoimmunity. Our work correlates for the first time detailed immunological findings and infectious events in adult patients with DS. Despite persistent T and B cell alterations, young ambulatory adults with DS have a low risk of infections, suggesting offsetting mechanisms in adulthood. However, infections, mostly bacterial aspiration pneumonia, remain the first cause of hospitalization. The major factor associated with infectious complications and premature death is the occurrence of neurological diseases such as seizures and dementia [23]. Seizures are frequent in adults with Down’s syndrome with about 10 times increased incidence as compared to general population. Seizures are associated with aging and cognitive impairment in DS [24]. Development of dementia in DS syndrome dramatically increases after age of 40 and is one of the main cause of institutionalization and hospitalization [4, 24]. Considering pediatric studies and our work, infections in DS occur early in life up and in the second adulthood period -after 50 years-old- especially when neurological comorbidities are associated. Indeed, neurological impairment marks a turning point in the infectious complications of adults patients with DS and this should be kept in mind by physicians.
Anzeige
Acknowledgments
Additional contributions:
PHRC T21 study group: Emmanuel Andres, MD, PhD, Xavier Argemi, MD, PhD, Frédéric Blanc, MD, PhD, Isabelle Brun, MD, Salima El Chehadeh, MD, Jean-Luc Davideau, MD, Jean-Louis Dietemann, MD, PhD, Hélène Dollfus, MD, PhD, Elise Gazzano, MD, Bernard Goichot, MD, PhD, Julie Helms, MD, Jean-Michel Hiebel, MD, Georges Kaltenbach, MD, PhD, Anne Koenig, MD, PhD, Marie-Cécile Manière, PhD, Yaumara Perdomo, MD, Hélène Petit-Eisenmann, MD, PhD, Alain Pradignac, MD, PhD, Anne-Elisabeth Quoix, MD, PhD, Philippe Sauder MD PhD, Elise Schaefer, MD, Francis Schneider, MD, PhD, Dana Timbolschi, MD, Jean-Christophe Weber, MD (Strasbourg University Hospital) contributed clinical and administrative collaborative efforts. Insightful comments on the manuscript: Laurent Arnaud MD, PhD (Strasbourg University Hospital) and Hans Hartmut Peter MD, PhD (Universitätsklinikum Freiburg). No compensation was received.
We thank the patients, families and staff for their time and dedication.
Funding
Fundings/grants:
Dr. Yves Alembik (grant from the French Ministry of Health PHRC 2012-A00466–37),
Pr. Anne-Sophie Korganow (grant from EU-funded (ERDF) project INTERREG V “RARENET”).
Availability of data and materials
All data generated or analyzed during this study are included in this published article [and its additional files].
Ethics approval and consent to participate
Ambulatory patients involved in PHRC T21 “Trisomy 21 in Adulthood”: (Dr Alembik Yves): All subjects were recruited under a protocol approved by ethical board CPP-Est IV N°12/47 (research ethical board of Strasbourg University Hospital) including a written informed consent.
Anzeige
Retrospective hospitalized patients: An approval statement from the local ethical committee has been obtained (ethical committee of the Faculties of Medicine and Dentistry of Strasbourg N°2018–8).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Anzeige
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.